Skip to content

US · ATEC · MEDICAL - DEVICES

Alphatec Holdings, Inc. (ATEC) intrinsic value and stock valuation

$6.68as of 2026-11-21 · Mkt cap 1.47B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Alphatec Holdings, Inc. DCF and intrinsic value

InvestorsCraft values ATEC with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ATEC’s statements →

Alphatec Holdings, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Carlsbad, CA 92008 atecspine.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$764.2M+39.5% 5y CAGRd
20112025
Net income
-$-143.36M
20112025
Free cash flow
$2.78M
20112025
Total equity
$36M-25.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$764.2M$611.6M$482.3M$350.9M$243.2M
Operating income-$-82.13M-$-136.17M-$-173.4M-$-146.97M-$-128.06M
Net income-$-143.36M-$-162.12M-$-186.64M-$-151.29M-$-143.03M
EPSd-$-955.35K-$-1.13M-$-1.54M-$-1.46M-$-1.49M
Operating cash flow$45.2M-$-44.65M-$-78.48M-$-75.13M-$-73.32M
Capital expenditure-$-42.45M-$-93.14M-$-86.97M-$-58.28M-$-68.54M
Free cash flow$2.78M-$-137.79M-$-165.46M-$-133.41M-$-141.86M
Total assets$791.2M$775.7M$805.2M$521M$572.1M
Total debt$620M$609.9M$541.7M$395.9M$355.4M
Net debt$459.1M$471.1M$320.7M$311.2M$168.2M
Total equity$36M$9.43M$101.7M-$-34.67M$79.4M
Cash and short-term investments$160.8M$138.8M$221M$84.7M$187.3M
Income statement
20252024202320222021
Revenue$764.2M$611.6M$482.3M$350.9M$243.2M
Cost of revenue$232.3M$187.3M$172.1M$117.8M$85.5M
Gross profit$531.9M$424.3M$310.2M$233.1M$157.8M
Research and development expenses$76.3M$80.7M$70.1M$44M$32M
Selling, general and administrative expenses$498.5M$450.2M$374.1M$300M$229.3M
Other expenses$39.2M$29.5M$39.4M$36M$24.5M
Operating expenses$614M$560.4M$483.6M$380M$285.8M
Cost and expenses$846.3M$747.7M$655.7M$497.8M$371.3M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$21.1M$24.9M$16.6M$5.5M$7.11M
Depreciation and amortization$82.6M$83.3M$59.7M$43.9M$30.2M
Ebitda-$-39.7M-$-53.87M-$-110.59M-$-102.58M-$-106.88M
Operating income-$-82.13M-$-136.17M-$-173.4M-$-146.97M-$-128.06M
Total other income/expenses, net-$-61.27M-$-25.9M-$-13.52M-$-5.03M-$-16.11M
Income before tax-$-143.4M-$-162.07M-$-186.91M-$-152.01M-$-144.16M
Income tax expense-$-40K$50K-$-280K-$-720K-$-1.13M
Net income-$-143.36M-$-162.12M-$-186.64M-$-151.29M-$-143.03M
Weighted average shares outstanding$150.1M$143M$121.2M$103.4M$96.2M
Weighted average diluted shares outstanding$150.1M$143M$121.2M$103.4M$96.2M
Balance sheet
20252024202320222021
Cash and short-term investments$160.8M$138.8M$221M$84.7M$187.3M
Net receivables$97.3M$83M$72.6M$60.1M$41.9M
Inventory$169.4M$175.3M$136.8M$101.5M$91.7M
Total current assets$450.9M$417.4M$451.1M$255.6M$331.2M
Property, plant and equipment, net$166.6M$191.1M$176.3M$130.3M$112.7M
Goodwill and intangible assets$168.7M$164.5M$175.5M$130.2M$125M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$340.3M$358.3M$354.1M$265.3M$240.9M
Total assets$791.2M$775.7M$805.2M$521M$572.1M
Accounts payable$40.9M$53M$49M$34.7M$25.7M
Short-term debt$70.8M$8.11M$6.97M$19.8M$4.55M
Deferred revenue$10.4M$10.5M$13.9M$12M$15.3M
Total current liabilities$219.2M$153M$157.6M$138.9M$101.1M
Long-term debt$549.1M$601.8M$534.7M$376.1M$350.9M
Deferred revenue, non-current$2.18M$3.13M$2.56M$3.05M$2.9M
Total non-current liabilities$536M$613.3M$545.9M$416.8M$391.5M
Capital lease obligations$23.9M$33.8M$28.8M$31.4M$28.6M
Total liabilities$755.2M$766.3M$703.5M$555.6M$492.6M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-1.42B-$-1.28B-$-1.12B-$-932.32M-$-782.33M
Accumulated other comprehensive income (loss)-$-4.43M-$-13.68M-$-8.32M-$-10.79M-$-5.99M
Total equity$36M$9.43M$101.7M-$-34.67M$79.4M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$620M$609.9M$541.7M$395.9M$355.4M
Net debt$459.1M$471.1M$320.7M$311.2M$168.2M
Cash flow statement
20252024202320222021
Net income-$-143.36M-$-162.12M-$-186.64M-$-151.29M-$-143.03M
Depreciation and amortization$105.1M$83.3M$59.7M$43.9M$30.2M
Stock-based compensation$73.7M$73.3M$81.2M$40.6M$36.5M
Change in working capital-$-20.13M-$-67.27M-$-54.18M-$-23.94M-$-25.05M
Accounts receivable-$-21.88M-$-14.59M-$-12.79M-$-18.83M-$-10.14M
Inventory$13.5M-$-54.66M-$-45.56M-$-20.7M-$-27.75M
Accounts payable-$-11.16M$9.67M$6.99M$9.8M$760K
Net cash provided by operating activities$45.2M-$-44.65M-$-78.48M-$-75.13M-$-73.32M
Investments in property, plant and equipment-$-42.45M-$-83.22M-$-80.51M-$-49.45M-$-68.54M
Acquisitions, net$0.00$0.00-$-55M$0.00-$-83.23M
Net cash used for investing activities-$-53.41M-$-93.14M-$-141.97M-$-58.28M-$-157.76M
Common stock issued$520K-$-560K$212.1M-$-3.04M$131.8M
Common stock repurchased$0.00$0.00$0.00$0.00-$-30.96M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$30M$56.2M$356.9M$31.2M$312M
Net change in cash$22M-$-82.13M$136.3M-$-102.55M$79.5M
Cash at end of period$160.8M$138.8M$221M$84.7M$187.3M
Operating cash flow$45.2M-$-44.65M-$-78.48M-$-75.13M-$-73.32M
Capital expenditure-$-42.45M-$-93.14M-$-86.97M-$-58.28M-$-68.54M
Free cash flow$2.78M-$-137.79M-$-165.46M-$-133.41M-$-141.86M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Alphatec Holdings, Inc.

        Alphatec Holdings, Inc. is a medical technology firm dedicated to engineering and advancing solutions for the surgical management of spinal conditions. Its product array includes the Alpha InformatiX platform, notably the SafeOp Neural InformatiX System, which is engineered to reduce the likelihood of nerve injury during surgery. For access and positioning, Alphatec offers systems such as the Sigma transforaminal lumbar interbody fusion pedicle-based access system, the Sigma PTP Access and Patient Positioning System, and the Squadron lateral retractor, all designed to optimize surgical outcomes. The company's robust line of spinal fixation devices features the Invictus Spinal Fixation System, capable of addressing various thoracolumbar pathologies, alongside its minimally invasive SingleStep System and adaptable Modular Fixation Systems, which enhance screw modularity. Further fixation options include the OsseoScrew system for spinal column restoration and the comprehensive Arsenal spinal fixation platform, catering to a spectrum of degenerative to deformity procedures. Alphatec also provides anterior lumbar plating solutions like the Aspida Anterior Lumbar Plating System for interbody fusion and the AMP Anti-Migration Plate, in addition to cervical fixation options such as the OCT Spinal Fixation System, the Trestle Luxe Anterior Cervical Plate System, and the Insignia Anterior Cervical Plate System. Its portfolio extends to interbody implants, including IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Implants. A comprehensive suite of biologics is also available, featuring Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. The company additionally offers EOS imaging products. Alphatec Holdings markets its diverse product range throughout the United States via a network of independent distributors and its own direct sales force. Established in 1990, the company's headquarters are located in Carlsbad, California.

        CEO
        Patrick S. Miles
        Employees
        913
        Beta
        0.85

        Explore

        Frequently asked questions

        What is the intrinsic value of Alphatec Holdings, Inc. (ATEC)?

        Alphatec Holdings, Inc. (ATEC) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ATEC undervalued?

        ATEC trades at a price of $6.68 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.